In Central and Eastern Europe (CEE) approximately 1,000 new studies are registered annually. Hungary and the Czech Republic take the largest share of this, with 250 – 300 clinical trial registrations per year in each.
Although there are fewer trials registered in Russia each year, Russia remains an important destination because of its wealth of sites and patients.
The CEE is one of the most dynamic and fastest-growing regions in Europe, and there are several advantages to placing clinical research studies in these areas, including:
(1) RAPID RECRUITMENT OF STUDY POPULATION
Numerous multinational clinical trials have demonstrated that the patient recruitment rate in CEE countries is significantly higher than in Western Europe or in the USA. Why?
(2) INVESTIGATORS ARE HIGHLY MOTIVATED AND LOYAL
Unlike their western counterparts, physicians in the CEE seek out and support clinical studies for many reasons, making them ideal partners for western sponsors. Why?
(3) REMARKABLE PRICE ADVANTAGE
Where can your study enjoy the advantages of a first-world infrastructure with the cost savings of a developing country? The CEE has many opportunities to magnify the impact of your clinical budget. How?
(4) LOCAL MONITORS ARE MORE SKILLED THAN AVERAGE
Without a doubt, around the world you will find that the professionals in pharma research are among the most highly educated and well-trained people. In the CEE, however, this tends to be even truer because of the unique social and economic dynamics here. Why?
(5) Excellent FDA Audit results in CEE
The graph below speaks for itself. The CEE leads the world in its ratio of highly successful audits by the FDA. And we have done it without any Official Actions Indicated!